Daré Bioscience completes Regulation A unit offering
Daré Bioscience, Inc. completed closings of its previously announced Regulation A unit offering.
Rhea-AI Filing Summary
Daré Bioscience, Inc. completed closings of its previously announced Regulation A unit offering. The company issued 50,000 Investor Units, each priced at $5.00, with each unit consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants.
In total, Daré issued 50,000 shares of Series A Preferred Stock and Investor Warrants to purchase up to 100,000 shares of common stock. The offering is conducted under an offering statement on Form 1-A qualified by the SEC on April 1, 2026, with related offering circulars dated January 6, March 26, and May 14, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 3.02 — Unregistered Sales of Equity Securities
1 item
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Key Figures
Reg A maximum offering size: 4,854,000 units
Investor Unit price: $5.00 per unit
Investor Units issued: 50,000 units
+3 more
6 metrics
Reg A maximum offering size
4,854,000 units
Previously announced Investor Unit offering size
Investor Unit price
$5.00 per unit
Offering price for each Investor Unit
Investor Units issued
50,000 units
Units issued at closing on May 14, 2026
Series A Preferred shares issued
50,000 shares
One share of Series A Preferred per Investor Unit
Common shares underlying warrants
100,000 shares
Shares of common stock purchasable via Investor Warrants
Form 1-A qualification date
April 1, 2026
Most recent SEC qualification of offering statement
Key Terms
Regulation A, Series A Convertible Preferred Stock, Investor Warrants, Form 1-A, +1 more
5 terms
Regulation A regulatory
"completed closings of its previously announced Regulation A offering of up to 4,854,000 units"
Regulation A is a U.S. securities rule that lets smaller or growing companies offer shares to the public with simpler paperwork and lower costs than a full stock market listing, acting as a middle ground between private fundraising and a traditional public offering. For investors it matters because it opens access to early-stage opportunities that would otherwise be private, but these offerings can carry higher risk and different disclosure standards than large, fully listed companies.
Series A Convertible Preferred Stock financial
"each consisting of one share of Series A Convertible Preferred Stock (the “Series A Preferred Stock”)"
Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.
Investor Warrants financial
"and two warrants, each to purchase one share of our common stock (“Investor Warrants”)"
Investor warrants are tradable rights that let the holder buy a company’s stock at a fixed price for a limited time. They matter because they can amplify returns if the share price rises above that fixed price, but they also can dilute existing shareholders if exercised; think of a warrant as a coupon that lets you purchase shares later at today’s price, creating potential upside for the holder and a future change in share count for investors.
Form 1-A regulatory
"pursuant to our offering statement on Form 1-A (File No. 024-12688), as amended"
offering circular regulatory
"the offering circular dated January 6, 2026, and the offering circular supplements"
An offering circular is a formal disclosure document provided to potential investors when a company or issuer makes securities available for sale. It lays out what is being sold, the price and terms, key financial facts, management background, intended use of proceeds and the main risks — like the product label and instruction manual for an investment. Investors use it to compare options and judge whether the risk and potential return fit their needs.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Daré Bioscience (DARE) disclose in its latest 8-K?
Daré Bioscience reported completing closings of its Regulation A offering of Investor Units. It issued 50,000 units, each at $5.00, consisting of Series A Convertible Preferred Stock and Investor Warrants to purchase common shares under a previously qualified Form 1-A offering statement.
How many Investor Units did Daré Bioscience (DARE) issue in the Regulation A offering?
Daré Bioscience issued 50,000 Investor Units in its Regulation A offering. Each unit includes one share of Series A Convertible Preferred Stock and two Investor Warrants, giving warrant rights to purchase up to 100,000 shares of the company’s common stock in total.
What are the key terms of Daré Bioscience (DARE) Investor Units?
Each Investor Unit is offered at $5.00 and consists of one share of Series A Convertible Preferred Stock plus two Investor Warrants. Each Investor Warrant allows the holder to purchase one share of common stock, providing additional potential equity exposure if warrants are exercised.
What securities did Daré Bioscience (DARE) issue as part of this offering?
Daré Bioscience issued 50,000 shares of Series A Convertible Preferred Stock and Investor Warrants to purchase up to 100,000 shares of common stock. These securities were issued through 50,000 Investor Units sold under a previously qualified Regulation A Form 1-A offering statement.
Under what regulatory framework was Daré Bioscience (DARE) conducting this offering?
The offering was conducted under Regulation A pursuant to an offering statement on Form 1-A, File No. 024-12688. This statement was most recently qualified by the SEC on April 1, 2026, supported by offering circulars dated January 6, March 26, and May 14, 2026.
When did Daré Bioscience (DARE) complete the closings of its Regulation A offering?
Daré Bioscience completed the closings of its Regulation A Investor Unit offering on May 14, 2026. The company’s 8-K describes the issuance of 50,000 Investor Units and references earlier SEC-qualified offering materials governing the conversion and exercise terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
